Trending...
- Update Any Sign Instantly with Santek EZ Sign NFC: Ultra-Slim 4-Color E-Paper Display - 132
- Hiclean Tools Releases HCX2100 Electric Pressure Washer
- Some Music for Donald's Bad Day
SANTA CLARA, Calif., July 22, 2021 /PRNewswire/ -- Frost & Sullivan's recent analysis, Global RNA Therapeutics: Technology Growth Opportunities, reveals that ribonucleic acid (RNA) therapeutics is poised to gain momentum in the next few years and can potentially be applied to a wide variety of disease interventions. Additionally, the growth opportunities exposed by the initial commercialization of mRNA vaccines, antisense oligonucleotides (ASOs) and short interfering RNA (siRNA)-based therapeutics are further attracting pharmaceutical and biotechnology companies to invest in this space and expedite research and development (R&D).
For further information on this analysis, please visit: http://frost.ly/62g
"Advances in RNA stability, manufacturing, chemical modification, and targeted delivery systems have led to the commercial translation of RNA therapeutics," said Ruplekha Choudhurie, TechVision Industry Analyst at Frost & Sullivan. "RNAs are relatively easy to manufacture, cost-effective, and can act on undruggable targets. As a result, academic labs and small biotech companies are accelerating RNA therapeutics research, alongside Tier 1 biopharmaceutical companies."
More on The Californer
- RetroSlang®'s DJ Retro Plushy Looks to Becomes Gen Z's Symbol of Cultural Appreciation
- Golden Paper Introduces TAD Hand Towel Technology, Ushering in a New Era of Premium Tissue Quality
- Obsessed with Street Cats? There's an App for That
- Pet Affordable Lab Services Now Open for Scheduling
- ReedSmith® Creates Founder-Investor Connections at The Investor Dating Game™ by Tech Coast Venture Network During LA Tech Week
Choudhurie added: "RNAs have certain advantages over deoxyribonucleic acid (DNA) and small molecule drugs, such as eliminating the risk of genomic integration, being relatively cost-effective, and having rapid development and production. Hence, RNA therapeutics investment has a better chance of commercial success and enables better returns in less time for market participants. Specifically, for the development of vaccines for COVID-19 and other emerging infectious disease outbreaks, mRNA vaccines have an advantage over other types of vaccines as they can be rapidly developed and amenable to modifications to target evolving viral variants."
The advantages of RNA therapeutics over conventional small molecule drugs and other biological drugs present immense growth opportunities for market players, including:
- Formulation and delivery of RNA therapeutics: Lipid-nanoparticles were used for delivery formulation in the previously approved RNA therapeutics, and similar (RNA-LNPs) formulations have been considered standard. Rapid formulation and delivery advances will improve the future of RNA delivery and help overcome the intrinsic stability issues of RNA.
- Stability of mRNA vaccines and RNA therapeutics at ambient temperature: Novel formulations that improve mRNA stability at ambient temperatures would facilitate the worldwide application of mRNA vaccines more rapidly and at a much lower cost. This will benefit mRNA vaccines and the entire RNA therapeutics field in general.
- mRNA vaccines and active participation of big pharmaceutical companies: Currently, RNA therapeutics is one of the fastest and most promising approaches in biological therapeutics. Due to this, many stakeholders are investing heavily in mRNA vaccines.
Global RNA Therapeutics: Technology Growth Opportunities is the latest addition to Frost & Sullivan's TechVision research and analyses available through the Frost & Sullivan Leadership Council, which helps organizations identify a continuous flow of growth opportunities to succeed in an unpredictable future.
More on The Californer
- Modern Myth TV Launches Kickstarter for Legend Hunterz, a Native-Led Paranormal & History Series
- OfficeSpaces.co Expands Its AI-Powered Website Builder Across North America
- Tobu Railway Group Will Host the Fourth Annual "Take-Akari" Bamboo Lantern Festival in East Tokyo, November 7, 2025 – January 31, 2026
- Branded Seats Folding Cup Holder Debuts at a NBA Arena
- California: ICYMI: Governor advances Delta Conveyance Project through two key milestones
About Frost & Sullivan
For six decades, Frost & Sullivan has been world-renowned for its role in helping investors, corporate leaders and governments navigate economic changes and identify disruptive technologies, Mega Trends, new business models, and companies to action, resulting in a continuous flow of growth opportunities to drive future success. Contact us: Start the discussion.
Global RNA Therapeutics: Technology Growth Opportunities
DA00
Contact:
Mariana Fernandez
Corporate Communications
E: [email protected]
http://ww2.frost.com
SOURCE Frost & Sullivan
Related Links
www.frost.com
Filed Under: Business
0 Comments
Latest on The Californer
- Long Beach Public Library to Host Unveiling Ceremony for Michelle Obama Neighborhood Library Courtyard
- Keebos Launches Crossbody Cases for Every iPhone 17 Model
- California: Governor Newsom announces judicial appointments
- WOA Crypto redefines cloud Bitcoin mining, offering free access and instant profit opportunities
- Pepperdine University Malibu, California and Community Partners Recognized with 2025 ReadyCommunities Partnership National Service Award
- Promise B Mae's "Baddies R Us" Grand Opening Earns City Recognition, Cardi B Cosign & Support
- California expands CalAssist Mortgage Fund Disaster Relief: More California families to qualify for mortgage grants
- NBA Overachievers: OddsTrader Reveals Which Teams Will Exceed Expectations in 2025-26
- Crypto Betting Odds 2025: Bookmakers Review Analyzes Market Predictions and Year-End Price Lines
- The OpenSSL Corporation and the OpenSSL Foundation Celebrate the Success of the Inaugural OpenSSL Conference in Prague
- DJ Expert Warns Couples: "Bargain Wedding DJs Are Backing Out for Higher-Paying Gigs Leaving Clients Scrambling"
- California to deploy National Guard to support food banks, fast-track funding as Trump's shutdown strips families of food benefits
- Aaron Akins' 'When Do We Love Tour' Arrives in Los Angeles at Catalina Jazz Club Nov. 5, 2025
- TKL Group's New Factory Commences Production, Pioneering A New Era In Global Heavy Duty Truck Parts
- Regulated Crypto Exchange TZNXG Addresses Core US Market Challenges with Compliance-First Infrastructure
- GitKraken Launches Insights to Help Engineering Leaders Quantify AI Impact and Improve Developer Experience
- ZapperBox NextGen TV Gateway Receiver Now Testing Support For Secure Whole-Home Content Distribution
- Life as a Dog: P-Wave Press Brings Readers a Heartwarming Memoir of Love, Laughter and Companionship
- NOYA Launches Premium, Design-Forward Training Gear That Belongs at the Center of Your Space
- Tanbii Raises $3 Million to Launch Web3 Game Lets You Plant Virtual Trees and See Real Trees Grow